Antibodies in diagnosis and therapy. The magic bullet--nearing the century mark

V Raso1

  • 1Boston Biomedical Research Institute, Department of Fine Structure Research, MA 02114.

Insights

Developing effective cancer therapies requires agents that precisely target and eliminate cancer cells without harming healthy tissues. Animal models guide the design of superior cancer-targeting agents by examining key features for therapeutic success.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • The ideal cancer therapy, a 'magic bullet,' must selectively eliminate all cancer cells while sparing normal tissues.
  • Achieving this requires agents with precise targeting, recognition, and permanent inactivation capabilities.

Purpose of the Study:

  • To evaluate animal models that approximate the criteria for successful 'magic bullet' cancer therapies.
  • To identify key features contributing to therapeutic success in these models.
  • To inform the design of improved targeted cancer agents.

Main Methods:

  • Analysis of animal models exhibiting varying degrees of 'magic bullet' criteria.
  • Consideration of factors like cellular receptors, internalization, toxin action, and pharmacokinetics.
  • Review of advanced biotechnological strategies for agent construction.

Main Results:

  • Animal models provide a framework for assessing current targeted agents.
  • Identified critical parameters for optimizing agent performance against cancer cells.
  • Highlighted the importance of balancing potency on target versus non-target cells.

Conclusions:

  • Animal models are crucial for understanding and improving targeted cancer therapy.
  • Further research should focus on optimizing agent delivery, specificity, and efficacy.
  • Advanced biotechnological approaches are key to developing next-generation cancer 'bullets'.

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Cross-reactivity00:42

Cross-reactivity

Overview
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Immunological Memory01:23

Immunological Memory

Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...